MariMed Announces Strategic Exit From Missouri Market
MariMed (CSE: MRMD / OTCQX: MRMD) announced it has completed a strategic review and is exiting the Missouri market, effective immediately.
Since 2024 the company managed another licensed operator's Missouri facility under a Managed Services and Licensing Agreement while awaiting a license transfer; MariMed will no longer manage the facility or pursue the license transfer. The company continues to own or manage revenue-generating operations in six states, including 13 dispensaries and six cultivation and processing facilities across Delaware, Illinois, Maryland, Massachusetts, Ohio, and Pennsylvania. MariMed said the exit is expected to improve gross margin and adjusted EBITDA and let management redeploy resources to higher-return core markets. Management said it may consider future licensing with a vertical operator in Missouri if financially sensible.
MariMed (CSE: MRMD / OTCQX: MRMD) ha annunciato di aver completato una revisione strategica ed esce dal mercato del Missouri, con effetto immediato.
Dal 2024 l'azienda ha gestito un altro operatore autorizzato presso l'impianto del Missouri sotto un Accordo di Servizi Gestiti e Licenze in attesa di trasferimento della licenza; MariMed non gestirà più l'impianto né perseguirà il trasferimento della licenza. L'azienda continua a possedere o gestire attività generate da ricavi in sei stati, inclusi 13 dispensari e sei impianti di coltivazione e lavorazione in Delaware, Illinois, Maryland, Massachusetts, Ohio e Pennsylvania. MariMed ha detto che l'uscita dovrebbe migliorare il margine lordo e l'EBITDA rettificato e permettere al management di ridistribuire risorse verso mercati principali ad alto rendimento. Il management ha detto che in futuro potrebbe considerare ulteriori licenze con un operatore verticale in Missouri se sensato dal punto di vista finanziario.
MariMed (CSE: MRMD / OTCQX: MRMD) anunció que ha completado una revisión estratégica y sale del mercado de Missouri, con efecto inmediato.
Desde 2024 la empresa gestionó las instalaciones de otro operador con licencia en Missouri bajo un Acuerdo de Servicios Gestionados y Licencias mientras esperaba la transferencia de la licencia; MariMed ya no gestionará la instalación ni perseguirá la transferencia de la licencia. La empresa continúa poseyendo o gestionando operaciones generadoras de ingresos en seis estados, incluyendo 13 dispensarios y seis instalaciones de cultivo y procesamiento en Delaware, Illinois, Maryland, Massachusetts, Ohio y Pensilvania. MariMed dijo que la salida se espera que mejore el margen bruto y el EBITDA ajustado y permita a la dirección reasignar recursos a mercados principales de mayor rendimiento. La dirección dijo que podría considerar licencias futuras con un operador vertical en Missouri si tiene sentido financiero.
MariMed(CSE: MRMD / OTCQX: MRMD)은 전략적 검토를 완료하고 Missouri 시장에서 즉시 퇴출하기로 했다고 발표했습니다.
2024년부터 회사는 라이선스를 보유한 다른 운영자의 미주리 시설을 관리하는 매니지드 서비스 및 라이선싱 계약 아래에서 대기 중인 라이선스 이전을 기다렸습니다; MariMed는 더 이상 시설을 관리하지 않으며 라이선스 이전도 추구하지 않습니다. 회사는 여전히 델라웨어, 일리노이, 메릴랜드, 매사추세츠, 오하이오, 펜실베이니아에 걸쳐 6개 주에서 수익 창출 운영을 소유하거나 관리하고 있으며, 13개의 디스펜서와 6개의 재배 및 가공 시설을 포함합니다. MariMed는 퇴출이 총마진과 조정 EBITDA를 개선하고 관리진이 자원을 더 높은 수익의 핵심 시장으로 재배치하도록 할 것이라고 말했습니다. 경영진은 재정적으로 타당하다면 Missouri의 수직적 운영자와의 향후 라이선스를 고려할 수 있다고 말했습니다.
MariMed (CSE: MRMD / OTCQX: MRMD) a annoncé avoir terminé une revue stratégique et quitter le marché du Missouri, avec effet immédiat.
Depuis 2024, l'entreprise gérait l'installation d'un autre opérateur agréé dans le Missouri sous un accord de services gérés et de licences en attendant le transfert de licence; MariMed ne gérera plus l'installation ni ne poursuivra le transfert de licence. L'entreprise continue de posséder ou de gérer des activités génératrices de revenus dans six États, comprenant 13 dispensaires et six installations de culture et de traitement à travers le Delaware, l'Illinois, le Maryland, le Massachusetts, l'Ohio et la Pennsylvanie. MariMed a déclaré que la sortie devrait améliorer la marge brute et l'EBITDA ajusté et permettre à la direction de réaffecter les ressources vers les marchés principaux à rendement élevé. La direction a déclaré qu'elle pourrait envisager de futures licences avec un opérateur vertical dans le Missouri si cela est financièrement envisageable.
MariMed (CSE: MRMD / OTCQX: MRMD) gab bekannt, dass es eine strategische Überprüfung abgeschlossen hat und den Missouri-Markt mit sofortiger Wirkung verlässt.
Seit 2024 verwaltete das Unternehmen die Missouri-Anlage eines anderen lizenzierten Betreibers unter einer Managed Services and Licensing Agreement, während auf die Lizenzübertragung gewartet wurde; MariMed wird die Anlage nicht mehr verwalten oder die Lizenzübertragung verfolgen. Das Unternehmen besitzt oder verwaltet weiterhin umsatzgenerierende Betriebe in sechs Bundesstaaten, darunter 13 Dispensaries und sechs Anbau- und Verarbeitungsanlagen in Delaware, Illinois, Maryland, Massachusetts, Ohio und Pennsylvania. MariMed sagte, der Ausstieg könne die Bruttomarge und das bereinigte EBITDA verbessern und dem Management ermöglichen, Ressourcen in margenstärkere Kernmärkte umzuschichten. Das Management sagte, es könnte in Zukunft eine Lizenz mit einem vertikalen Betreiber in Missouri prüfen, falls finanziell sinnvoll.
ماري ميد (CSE: MRMD / OTCQX: MRMD) أعلنت أنها أنهت المراجعة الاستراتيجية وتخرج من سوق ميسوري، اعتباراً من الآن.
منذ عام 2024 أدارت الشركة منشأة لمشغّل مرخّص آخر في ميسوري بموجب اتفاق خدمات مُدارة وترخيص في انتظار نقل الترخيص؛ لن تدير MariMed المنشأة بعد الآن ولن تسعى لنقل الترخيص. لا تزال الشركة تملك أو تدير عمليات تولّد إيرادات في ست ولايات، بما في ذلك 13 صيدلية و6 مرافق للزراعة والمعالجة عبر Delaware وIllinois وMaryland وMassachusetts وOhio وPennsylvania. قالت MariMed إن الخروج من المتوقع أن يحسن الهامش الإجمالي وEBITDA المعدل وأن يسمح للإدارة بإعادة توزيع الموارد نحو الأسواق الأساسية ذات العائد الأعلى. قالت الإدارة إنها قد تفكر في تراخيص مستقبلية مع مشغّل عمودي في ميسوري إذا كان ذلك منطقياً مالياً.
MariMed（CSE: MRMD / OTCQX: MRMD）宣布已完成战略评估并立即退出密苏里市场。
自2024年以来，公司在等待许可转让的同时，在密苏里州的一个获得许可的运营商设施下，按“托管服务和许可”协议进行管理；MariMed 将不再管理该设施，也不再推进许可转让。公司仍在六个州拥有或管理产生收入的业务，其中包括在特拉华州、伊利诺伊州、马里兰州、马萨诸塞州、俄亥俄州和宾夕法尼亚州的13家药房和6个种植与加工设施。MariMed 表示，此次退出有望提升毛利率和经调整后的EBITDA，并让管理层将资源重新投入到更高回报的核心市场。管理层表示如果在财务上可行，未来可能考虑与密苏里州的垂直运营商进行许可事宜。
- Retains 13 dispensaries and six cultivation/processing facilities
- Exit intended to improve gross margin
- Exit intended to improve adjusted EBITDA
- Management to reallocate resources to core, higher-return markets
- Immediate loss of Missouri market presence
- Company stopped pursuing license transfer and stopped managing facility
- Brands no longer distributed via managed Missouri operations
NORWOOD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, today announced that it has completed a strategic review of its Missouri business operations and decided to exit the market, effectively immediately.
Since 2024, the Company has managed the Missouri operations of another licensed cannabis operator and distributed certain of its brands there under a Managed Services and Licensing Agreement, while awaiting license transfer approval from the state. The Company will no longer manage the facility and will no longer seek the license transfer.
MariMed continues to own or manage revenue-generating operations in six states, including 13 dispensaries and six cultivation and processing facilities in Delaware, Illinois, Maryland, Massachusetts, Ohio, and Pennsylvania. Exiting Missouri is expected to improve the Company’s overall financial performance, particularly gross margin and adjusted EBITDA, and allow management to focus resources on higher return opportunities.
“Our brands performed well in the select stores where they were available in Missouri, but we concluded that reaching scale would have required significant resources we believe are better utilized in our core markets, where MariMed has established strong retail and wholesale positions,” said MariMed CEO Jon Levine. “Moving forward, we will consider licensing opportunities in Missouri with a vertical operator if it makes financial sense and supports our goal of becoming a cannabis CPG powerhouse.”
About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty's Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.
IMPORTANT CAUTION REGARDING FORWARD-LOOKING STATEMENTS:
The information in this release contains “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which are subject to several risks and uncertainties. All statements other than statements of historical facts contained in this release, including without limitation statements regarding projected financial results for 2025, including anticipated openings of dispensaries and facilities, timing of regulatory approvals, plans and objectives of management for future operations, are forward-looking statements. Without limiting the foregoing, the words “anticipates”, “believes”, “estimates”, “expects”, “expectations”, “intends”, “may”, “plans”, and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Forward-looking statements are based on our current beliefs and assumptions regarding our business, timing of regulatory approvals, the ability to obtain new licenses, business prospects and strategic growth plan, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated in these forward-looking statements due to various risks, uncertainties, and other important factors, including, among others, reductions in customer spending, our ability to recruit and retain key personnel, and disruptions from the integration efforts of acquired companies.
These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect our business and results of operations. These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment. Additional information regarding these and other factors can be found in our reports filed with the U.S. Securities and Exchange Commission. In providing these forward-looking statements, the Company expressly disclaims any obligation to update these statements publicly or otherwise, whether as a result of new information, future events or otherwise, except as required by law.
All trademarks and service marks are the property of their respective owners.
Neither the CSE nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.
Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007
FAQ
What did MariMed (MRMD) announce on October 28, 2025 about Missouri?
How many dispensaries and facilities does MariMed (MRMD) continue to operate after exiting Missouri?
Why did MariMed (MRMD) decide to exit Missouri on October 28, 2025?
Will MariMed (MRMD) return to Missouri after the October 28, 2025 exit?
Did MariMed (MRMD) manage the Missouri facility before the October 28, 2025 exit?
